We are conducting a research study to evaluate the safety, pharmacokinetics and efficacy of orally administered study drug for the treatment of nonhospitalized, symptomatic pediatric participants with COVID-19 who are at risk of progression of severe disease. This study may include multiple visits. Upon completion of the study visit(s), you will be paid for your time.
Male or female participants:
Cohort 1: Weight: greater than or equal to 88 lbs
Cohort 2: Weight: greater than or equal to 44 lbs to less than 88 lbs
Cohort 3: Age Group: 2 year age to less than 6 year age
Cohort 4: Age Group: 1 month age to less than 2 year age
Cohort 5: Age Group: less than 1 month age